Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
preoperative short-course radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Neoplasms
1 trial -
probiotics, antibiotics or antidepressants
The First People's Hospital of Lianyungang
Irritable Bowel Syndrome
1 trial -
recombinant human erythropoietin
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
recombinant human thrombopoietin
The First People's Hospital of Lianyungang
Immune Thrombocytopenia
1 trial -
recombinant human thrombopoietin (rhTPO); dexamethasone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
recombinant human thrombopoietin (rhTPO); rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
rhTPO
The First People's Hospital of Lianyungang
Immune Thrombocytopenia
1 trial -
rhTPO in combination with Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
rituximab; recombinant human thrombopoietin (rhTPO)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
robot-assisted surgery
Hospital Authority, Hong Kong
Rectal Cancer
1 trial -
rt-PA
Beijing Tiantan Hospital
Acute Ischemic Stroke
1 trial -
serplulimabγbevacizumab
Changhai Hospital
Rectal Cancer
1 trial -
shenfu injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Septic Shock
1 trial -
six courses of zanubrutinib, rituximab and lenalidomide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-Cell Lymphoma
1 trial -
tacrolimus capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lupus Nephritis
1 trial -
the Shouhui Tongbian Capsule
The First People's Hospital of Lianyungang
OIC
1 trial -
ticagrelor
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Cancer
1 trial -
total knee arthroplasty
Hospital Authority, Hong Kong
Osteoarthritis, Knee
1 trial -
urapidil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke, Acute
1 trial -
venetoclax
The First People's Hospital of Lianyungang
Acute Promyelocytic Leukemia
1 trial -
"Endostar"
The First People's Hospital of Lianyungang
Esophageal
1 trial -
-
Ningbo Cancer Hospital
Unresectable intrahepatic cholangiocarcinoma
1 trial -
0.2mg group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Opioid Dependence
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources